Tempest Therapeutics, Inc. (TPST): Entry into a Material Definitive Agreement
Tempest Therapeutics, Inc. (TPST) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On August 13, 2026, Tempest Therapeutics, Inc., a Delaware corporation (the “ Company ”), entered into a purchase agreement (the “ Purchase Agreement ”) and a registration rights agreement (the “ Registration Rights Agreement
How this was made
The 30-second read
Why it matters
The agreement’s accelerated purchase mechanics (discount to VWAP/close and minimum price thresholds) can increase trading volatility and perceived dilution risk if purchases commence.
Market read
Traders should reassess TPST’s near-term supply/dilution risk and potential discount-driven selling if the investor begins accelerated purchases.
What to watch
Key terms like total size, draw schedule, and any conditions precedent are not visible in the excerpt; those details can materially change dilution and near-term trading impact.
Background
The 8-K reports entry into a material definitive agreement and unregistered equity sales, consistent with a structured equity financing with a dedicated investor.
Ticker impact
Tempest Therapeutics entered a material definitive purchase agreement with Lincoln Park Capital Fund for up to an “Available Amount” of TPST common stock.
Near-term volatility risk is elevated; price may face downward pressure if the investor begins accelerated purchases at a discount to VWAP.
The filing discloses an equity purchase agreement with an investor and detailed accelerated purchase pricing (96% of lower VWAP/close) plus minimum price thresholds, which typically affects trading via dilution and discount-driven supply.
Market effects
Adds another example of small-cap biotech using investor purchase agreements, which can weigh on sentiment for similarly capital-constrained issuers.
No clear regional spillover indicated by the filing excerpt.
Limited, as this is company-specific financing documentation.
Counterpoint
If the company’s cash runway improves and the investor’s purchases are slow or capped, the market may look through dilution and focus on financing certainty.
Key entities
- issuerTempest Therapeutics, Inc.
Company filing the 8-K and entering the purchase agreement for its common stock.
- investorLincoln Park Capital Fund, LLC
Counterparty investor purchasing TPST common stock under the agreement.
